These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3922441)

  • 1. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 2. Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.
    Murphy DL; Tamarkin L; Sunderland T; Garrick NA; Cohen RM
    Psychiatry Res; 1986 Feb; 17(2):119-27. PubMed ID: 3008207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical effects of L-deprenyl in atypical depressives.
    Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
    Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
    Mendlewicz J; Youdim MB
    Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet serotonin response to treatment in geriatric depression.
    McIntyre IM; Norman TR
    Biol Psychiatry; 1989 Aug; 26(4):434-6. PubMed ID: 2765604
    [No Abstract]   [Full Text] [Related]  

  • 6. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
    J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
    [No Abstract]   [Full Text] [Related]  

  • 7. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
    Mann J; Gershon S
    Life Sci; 1980 Mar; 26(11):877-82. PubMed ID: 6768943
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
    Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Cohen RM; Newhouse PA; Mueller EA; Murphy DL
    J Clin Psychopharmacol; 1988 Feb; 8(1):23-7. PubMed ID: 3127432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tranylcypromine stereoisomers on depressive syndromes.
    Rüther E; Jungkunz G; Greil W; Zimmer R
    Mod Probl Pharmacopsychiatry; 1983; 19():203-10. PubMed ID: 6865964
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet monoamine oxidase inhibition as a potential indicator of favorable response to MAOI's in geriatric depressions.
    Georgotas A; Mann J; Friedman E
    Biol Psychiatry; 1981 Oct; 16(10):997-1001. PubMed ID: 7306621
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of isocarboxazid on platelet MAO activity.
    Davidson J; White H
    Biol Psychiatry; 1983 Sep; 18(9):1075-9. PubMed ID: 6640004
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-Deprenyl in atypical depressives.
    Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
    Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.
    Emory H; Mizrahi N
    J Diabetes Sci Technol; 2016 Sep; 10(5):1203-4. PubMed ID: 26961977
    [No Abstract]   [Full Text] [Related]  

  • 18. On the mode of action of L-deprenyl in the human central nervous system.
    Riederer P; Youdim MB; Rausch WD; Birkmayer W; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):217-26. PubMed ID: 745014
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
    Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
    Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.